Skip to Content
MIT News: 77 Mass Ave

How immune are you?

In just 10 minutes, this. covid diagnostic could tell you whether you might want to get a booster or take extra precautions.

October 25, 2022
Antibodies encircling a SARS-CoV-2 virus
Getty Images

Even if you’ve gained some immunity to covid-19 by getting vaccinated or recovering from the disease, it’s hard to know how vulnerable you might still be. Now MIT researchers have developed an easy-to-use test that may reveal just that. Using the “lateral flow” technology familiar from home covid and pregnancy tests, it measures the level of neutralizing antibodies against the SARS-CoV-2 virus in a tiny blood sample collected from a finger prick.

Easy access to this kind of test could help people determine what kind of precautions they should take, such as getting an additional booster. “Among the general population, many people probably want to know how well protected they are,” says Hojun Li, a physician and a lab head at MIT’s Koch Institute for Integrative Cancer Research, the senior author of a paper on the technique. “But I think where this test might make the biggest difference is for anybody who is receiving chemotherapy, anybody who’s on immunosuppressive drugs for rheumatologic disorders or autoimmune diseases, and anybody who’s elderly or doesn’t mount good immune responses in general.”

Li normally studies blood cell development and how blood cells become cancerous, not infectious diseases or diagnostics. So to develop this test, he sought advice from MIT faculty members Hadley Sikes and Sangeeta Bhatia, SM ’93, PhD ’97, who have expertise in the technology. With their help, his lab developed a device that can measure the amount of antibodies that block the SARS-CoV-2 receptor binding domain (RBD) from binding to ACE2, the human receptor the virus uses to infect cells.

The first step in the test is to add the blood sample to viral RBD protein that has been labeled with tiny gold particles. A few drops of the sample are then placed on a paper strip with two test lines embedded in it.

One of these lines attracts free viral RBD proteins, while the other attracts any RBD that has been captured by neutralizing antibodies. A strong signal from the second line indicates a high level of neutralizing antibodies in the sample, meaning you’re well protected. The results can be read in about 10 minutes. For a more precise measurement of antibody levels, a smartphone app can measure the intensity of each line and calculate the ratio of neutralized to infectious RBD protein.

When the researchers tested their device in about 60 people who had been infected with SARS-CoV-2 and 30 who had not, results were similar in accuracy to lab tests. The team also tested a series of samples from two people before they received a vaccine and at several points afterwards. Their level of neutralizing antibodies peaked around seven weeks after the first of two doses and then slowly declined to about 10% of the peak.

The test could be easily adapted to different variants of SARS-CoV-2 by swapping in new proteins, Li says. The researchers now hope to partner with a diagnostics company that can license and manufacture large quantities of the tests and obtain FDA approval for their use.

Keep Reading

Most Popular

Here’s how a Twitter engineer says it will break in the coming weeks

One insider says the company’s current staffing isn’t able to sustain the platform.

Technology that lets us “speak” to our dead relatives has arrived. Are we ready?

Digital clones of the people we love could forever change how we grieve.

How to befriend a crow

I watched a bunch of crows on TikTok and now I'm trying to connect with some local birds.

Starlink signals can be reverse-engineered to work like GPS—whether SpaceX likes it or not

Elon said no thanks to using his mega-constellation for navigation. Researchers went ahead anyway.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.